艾美疫苗迭代升級技術的人二倍體狂犬疫苗獲批開展臨床效價顯著高於已上市的人二倍體狂苗

By PR Newswire on 10 Mar 2025

PR Newswire (www.prnasia.com), a Cision company, is the premier global provider of media monitoring platforms and news distribution services that marketers, corporate communicators and investor relations professionals leverage to engage key audiences. Having pioneered the commercial news distribution industry since 1954, PR Newswire today provides end-to-end solutions to produce, distribute, target and measure text and multimedia content across traditional, digital, mobile and social channels. Combining the world's largest multi-channel content distribution and optimization network with comprehensive workflow tools and platforms, PR Newswire powers the stories of organizations around the world. PR Newswire serves tens of thousands of clients from offices in the Americas, Europe, Middle East, Africa and Asia-Pacific regions.

香港2025年3月10日 /美通社/ -- 國內疫苗龍頭企業 – 艾美疫苗（06660.HK）3月9日發出公告，公司研發的人二倍體狂犬疫苗，已於近日獲得國家藥品監督管理局《藥物臨床試驗批准通知書》。該產品是一款迭代升級的人二倍體狂犬疫苗，具有超高效價的明顯特點，也是全球狂犬疫苗技術領域的一次重大迭代升級。動物試驗表明，該疫苗免疫後可產生高保護水準的抗體，在同一劑量條件下，效價顯著高於已上市的人二倍體狂犬疫苗。